Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis' Taxotere Gets Breast Cancer Claim With 25.7% Reduction In Relapse Risk

This article was originally published in The Pink Sheet Daily

Executive Summary

A 1,491-patient study shows overall survival was longer with the docetaxel arm over the TAC and FAC regimens. The approval is the second new indication for Taxotere in the last three months.
Advertisement

Related Content

Abraxane Cost-Benefit Data Could Support Price Premium Over Taxol, Taxotere
Abraxane Cost-Benefit Data Could Support Price Premium Over Taxol, Taxotere
Lilly's Alimta Approved For Lung Cancer; "Reasonably Likely" To Improve Survival
Lilly's Alimta Approved For Lung Cancer; "Reasonably Likely" To Improve Survival
Lilly's Alimta Approved For Lung Cancer; "Reasonably Likely" To Improve Survival
Taxotere Would Be Unaffected By Alimta Approval, Aventis Says
Aventis Taxotere For Prostate Cancer Clears FDA With 2.5 Month Survival Benefit
Aventis Taxotere For Prostate Cancer Clears FDA With 2.5 Month Survival Benefit

Topics

Advertisement
UsernamePublicRestriction

Register

PS060327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel